Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes

Carolina B. Lopez, T. Dharma Rao, Helen Feiner, Richard Shapiro, Jeffrey R. Marks, Alan B. Frey

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Human breast carcinoma tumor-infiltrating lymphocytes (TIL) express activation antigens in situ indicative of ongoing immune response - CD28, CD45RO, CD69, CD71, and DR. However, interleukin 2 (IL-2) receptor was poorly expressed: CD25 was detected in only 1/24 samples and CD122 in only 2/24 samples. Furthermore, isolated breast cancer TIL were defective in proliferative response but recover when treated with recombinant IL-2. Nineteen of 24 tumor samples expressed B7-1, B7-2, and CD28 protein, showing that absence of costimulator proteins or counter ligand was not the basis for TIL proliferative deficit. Expression of IL-2 activity was not detected; however, mRNA encoding IL-2 was produced and translatable in vitro. These findings show that human breast cancer tumor-induced repression of IL-2 RNA translation is the basis of failure of TIL to express the IL-2 receptor and subsequent T cell hyporesponsiveness.

Original languageEnglish
Pages (from-to)141-155
Number of pages15
JournalCellular Immunology
Volume190
Issue number2
DOIs
StatePublished - Dec 15 1998

Keywords

  • Human breast cancer
  • IL-2 receptor
  • Immune response
  • Translation repression
  • Tumor-infiltrating lymphocytes

Fingerprint

Dive into the research topics of 'Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes'. Together they form a unique fingerprint.

Cite this